ADC Therapeutics SA announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster June 09, 2023 at the European Hematology Association 2023 Hybrid Congress (EHA2023) and will also be featured in an oral presentation at the 17th International Conference on Malignant Lymphoma (17-ICML) being held in Lugano, Switzerland from June 13-17, 2023. The multicenter, open-label, single-arm Phase 2 LOTIS-2 study that evaluated ZYNLONTA in patients with relapsed or refractory DLBCL after =2 prior systemic therapies resulted in an overall response rate (ORR) of 48.3% (70/145), with a complete response (CR) rate of 24.8% (36/145).

The median (range) time to response was 41.0 (35 to 247) days for all responders and 42.0 (36 to 247) days for patients with a CR. All-grade treatment-emergent adverse events occurring in =30% of all patients were increased gamma-glutamyltransferase (42%), neutropenia (40%), and thrombocytopenia (33%). Key data from 145 evaluable patients as of the data cutoff of September 15, 2022 include the following: The median duration of response (mDOR) was not reached for patients with a CR and was 13.37 months among all responding patients; Of the 36 patients with a CR, 11 (31%) were event-free for =2 years with no evidence of disease and no new anticancer therapy; In the subsets of patients who were event-free for =1 year and =2 years, the median (range) duration of time patients remained treatment-free post-ZYNLONTA was 24.8 (3.4 to 37.5) months and 27.7 (20.7 to 37.5) months, respectively; No new safety signals were identified.